Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab

SIMPLE SUMMARY: Denosumab, a bone-modifying agent, has been approved for the prevention of or reduction in skeletal-related events (SREs) in non-small cell lung cancer (NSCLC) patients with bone metastasis. However, the effect of denosumab on survival of epidermal growth factor receptor (EGFR)-mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, How-Wen, Chiu, Chi-Tsun, Wang, Chih-Liang, Yang, Tsung-Ying, Liu, Chien-Ying, Yu, Chih-Teng, Tseng, Li-Chuan, Kuo, Chih-Hsi Scott, Wang, Chin-Chou, Yang, Muh-Hwa, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316991/
https://www.ncbi.nlm.nih.gov/pubmed/35884531
http://dx.doi.org/10.3390/cancers14143470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316991/
https://www.ncbi.nlm.nih.gov/pubmed/35884531
http://dx.doi.org/10.3390/cancers14143470

Ejemplares similares